ArticleRespiratory research2026
GLCCI1 alleviates airway remodeling in asthmatic mice by inhibiting ZEB1-mediated epithelial-mesenchymal transition.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAsthma is a heterogeneous disease characterized by chronic airway inflammation and airway hyperresponsiveness. Our previous study found that glucocorticoid-induced transcript 1 (GLCCI1) is down-regulated in the lung tissues of asthmatic mice. This work attempted to determine the precise mechanism of GLCCI1 in asthma.
methodsThe asthma mouse model was constructed by administration of ovalbumin (OVA). OVA challenge elevated airway resistance and increased the levels of inflammatory factors (IL-1β, TNF-α, IL-13, TGF-β, IL-4, and IL-5) in the asthmatic mice. Histological analysis revealed enhanced inflammation and collagen deposition in lung tissues of asthmatic mice. GLCCI1 overexpression reduced airway resistance, lung inflammation, and fibrosis in asthmatic mice. In vitro, airway epithelial cells (BEAS-2B) were treated with TNF-α to mimic the condition of asthma.
resultsGLCCI1 overexpression enhanced the phosphorylation of PI3K, AKT, and mTOR, thereby activating the PI3K/AKT/mTOR signaling pathway in asthmatic mice and TNF-α-treated BEAS-2B. GLCCI1 up-regulation inhibited the expression of ZEB1, N-cadherin, Vimentin and elevated E-cadherin in asthmatic mice and TNF-α-treated BEAS-2B. The influence conferred by GLCCI1 overexpression was reversed by ZEB1 upregulation. It indicated that GLCCI1 suppressed ZEB1-mediated epithelial-mesenchymal transition (EMT). Both LY294002 (PI3K inhibitor) and Rapamycin (mTOR inhibitor) treatment reversed GLCCI1 overexpression-induced inhibition of ZEB1-mediated EMT in TNF-α-treated BEAS-2B.
conclusionIn summary, this work demonstrated that GLCCI1 overexpression inhibits ZEB1-mediated epithelial-mesenchymal transition by activating PI3K/AKT/mTOR signaling pathway, thereby alleviating airway remodeling in asthmatic mice. Thus, this study suggests that GLCCI1 may be a potential target for asthma treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.